EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 175 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Blind Customer Surprised With Sweet Message In Braille For Her Birthday August 28, 2021 Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical... April 6, 2023 Should People with Cancer and Cancer Survivors Get the Flu Vaccine? September 2, 2020 EMA Recommends Extension of Indications for Cemiplimab May 27, 2021 Load more HOT NEWS Connecting and Celebrating Preguntas frecuentes sobre el COVID-19 y el cáncer: Respuestas para pacientes... Autumn and Letting Go Addressing the Barriers to Minority Participation in Cancer Clinical Trials
